National Health Amendment Act 1989

Overview

The National Health Amendment Act 1989, enacted by the Parliament of Australia and assented to on 24 December 1989, serves to amend the National Health Act 1953 with a specific focus on the establishment, constitution, and procedure of the Pharmaceutical Benefits Remuneration Tribunal. This amendment was introduced to address gaps in the remuneration determination process for pharmaceutical services under the Pharmaceutical Benefits Scheme. The policy objective of the Act is to ensure that the Tribunal, which plays a crucial role in determining the remuneration for services provided under the Scheme, is constituted in a manner that reflects the interests of all stakeholders, including those previously engaged in community pharmacy. By amending the National Health Act 1953, the Act seeks to enhance the fairness and effectiveness of the remuneration determination process.

Scope and Application

The National Health Amendment Act 1989 is an Act of the Commonwealth of Australia that amends the National Health Act 1953, focusing on the establishment and procedure of the Pharmaceutical Benefits Remuneration Tribunal. The Act applies to the Tribunal itself and the individuals involved in its operations, including the appointment of additional members and the constitution and procedure of the Tribunal. The jurisdictional reach of the Act is national, as it is a Commonwealth Act. The Act does not specify exclusions, exemptions, or thresholds, but it does extend or restrict the application of the Principal Act through amendments and the creation of subordinate instruments, such as regulations and rules, which may provide further details on the operation and scope of the Tribunal. The Act also includes a transitional provision that allows inquiries commenced before the Act's commencement to continue as if the Tribunal was constituted in accordance with the amended Act.

Key Provisions

The National Health Amendment Act 1989 amends the National Health Act 1953 to modify the composition and procedures of the Pharmaceutical Benefits Remuneration Tribunal. Section 98a of the Principal Act is amended to increase the number of members from two to four, and to require the appointment of at least one additional member who has prior experience in community pharmacy (section 3). This appointment must be made after consulting with the Pharmacy Guild of Australia. Section 98bb is further amended to specify that the Tribunal must consist of at least three members, including the Chairperson, and allows the Chairperson to direct the constitution of the Tribunal for specific inquiries (section 4). Finally, section 98bc is revised to clarify that the Chairperson not only presides over proceedings but also has a deliberative vote and a casting vote in the event of a tie (section 5). The Act imposes specific obligations on the Minister regarding the appointment of Tribunal members, requiring the Minister to consult with the Pharmacy Guild of Australia before appointing any additional members with prior experience in community pharmacy (section 3). Furthermore, the Act mandates that the Tribunal must consist of at least three members, including the Chairperson, and provides the Chairperson with the authority to direct the constitution of the Tribunal for specific inquiries (section 4). It also stipulates that the Chairperson must preside over all proceedings and has a deliberative vote, with the added responsibility of casting a vote in the event of a tie (section 5). The Act does not explicitly outline specific offences or penalties for non-compliance with its provisions. However, given its nature and the context of health legislation, any failure to comply with the prescribed procedures for the establishment and operation of the Pharmaceutical Benefits Remuneration Tribunal could potentially lead to legal challenges regarding the validity of the Tribunal’s decisions. This might indirectly impact the enforceability of the Tribunal’s rulings, which could have significant implications for the parties involved in any disputes related to pharmaceutical benefits remuneration.